Novo Nordisk

Novo Nordisk’s Buyback Bet: Can a Paediatric Win Outweigh a Cardiology Programme Unravelling?

angelina -

Novo Nordisk Faces a September Reckoning as Oral Wegovy’s China Hopes Collide With Analyst Doubts

kashif hafeez -

Novo Nordisk’s Split Personality: Record US Scripts Versus a Pipeline That Just Won’t Cooperate

angelina -

Novo Nordisk’s Oral Wegovy Push Lands in Germany While a London Showdown Looms

kashif hafeez -

Novo Nordisk’s Krone-Sized Question: Can Buybacks Outweigh a Broken Pipeline Narrative?

Novo Nordisk’s Multi-Front Defense: Lawsuits, Buybacks, and a Split Decision on Wall Street

Novo Nordisk’s Contradictory Signals: A Downgrade, a Buyback, and a Race Against Lilly

Brett Shapiro -

Novo Nordisk’s Balancing Act: A Failed Heart Study, a Legal Win, and a Quiet Bet on Smaller Doses

Brett Shapiro -

Novo Nordisk’s Capital Discipline Meets a Market That’s Still Not Convinced

Brett Shapiro -

Novo Nordisk’s Defensive Posture: A Market Leader Fighting on Multiple Fronts

Novo Nordisk’s Confidence Gap: When Raised Guidance Isn’t Enough

kashif hafeez -

Novo Nordisk’s September Reckoning: A Raised Forecast That Failed to Soothe

Brett Shapiro -

Novo Nordisk’s Pipeline Setbacks Test the Patience of Investors Ahead of Earnings

Brett Shapiro -

Novo Nordisk’s Big Test: Can a Mass-Market Reality Replace the Miracle-Stock Narrative?

Brett Shapiro -

Novo Nordisk’s August Reckoning: A Failed Heart Drug, a Depressed Valuation, and Earnings That Could Go Either Way

kashif hafeez -
123...5Page 1 of 5